Carmell Therapeutics, a phase 2-stage biotechnology platform company, is set to go public through a merger deal with Alpha Healthcare Acquisition Corp. III, a special purpose acquisition company (SPAC). Post-closing, the combined business will be renamed Carmell Therapeutics Corporation, which is likely to be listed on the Nasdaq Capital Market. Assuming no redemption of shares […]
Carmell Therapeutics has secured clearance from the US Food and Drug Administration (FDA) for its investigational new drug application (IND) for CT-101, its first product, which is a bone healing accelerant (BHA). The Pennsylvania biotech company is engaged in the development and commercialization of plasma-based bioactive materials (PBMs) to speed up bone and soft tissue […]
